Pediatric Vaccine Market Report 2026

Pediatric Vaccine Market Overview

• Pediatric Vaccine market size has reached to $57.51 billion in 2025 • Expected to grow to $107.8 billion in 2030 at a compound annual growth rate (CAGR) of 13.5% • Growth Driver: Growing Prevalence Of Chronic Diseases In Children Boosts Pediatric Vaccine Market • Market Trend: Recent FDA Approval Of Vaccine Marks A Milestone In Pediatric Immunization • North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Pediatric Vaccine Market?

Pediatric vaccines refer to medications that are typically given to children as a form of protection against serious, frequently fatal diseases. They get the children’s body ready to battle the disease more quickly and successfully by boosting its natural defenses. The main types of pediatric vaccines are monovalent and multivalent. A monovalent vaccine is made up of only one antigen strain. The technology used includes live attenuated, inactivated, toxoid, conjugate, and other technologies to provide immunity from infectious disease, allergy, and cancer.

What Is The Pediatric Vaccine Market Growth Forecast?

The pediatric vaccine market size is expected to see rapid growth in the next few years. It will grow to $107.8 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to innovations in mRNA and DNA vaccines, increasing investment in pediatric vaccine R&D, digital health monitoring integration, expansion of emerging market healthcare infrastructure, partnerships between biotech firms and global health organizations. Major trends in the forecast period include increased focus on vaccine accessibility in low-income regions, rising adoption of combination vaccines, expansion of immunization programs in schools, development of novel pediatric vaccines for rare diseases, growing public-private partnerships in vaccine research.

Global Pediatric Vaccine Market Segmentation

1) By Vaccine Type: Monovalent, Multivalent 2) By Technology: Live Attenuated, Inactivated, Toxoid, Conjugate, Other Technologies 3) By Application: Infectious Disease, Allergy, Cancer Subsegments: 1) By Monovalent: Single Antigen Vaccines, Specific Disease Vaccines 2) By Multivalent: Combination Vaccines, Polyvalent Vaccines

What Are The Drivers Of The Pediatric Vaccine Market?

The rising prevalence of chronic diseases such as tuberculosis, diphtheria, and pneumonia in the age group of 15 years and below will contribute to the growth of the pediatric vaccines market. The risk of severe disease outcomes and complications of infectious diseases are increasing in children and adolescents with chronic conditions. For instance, in June 2024, according to the National Health Service, a UK-based government department, 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023, marking an 18% increase from 3,065,825 cases in 2022. Therefore, the rising prevalence of chronic diseases is driving the growth of the pediatric vaccine industry. The increasing prevalence of pediatric diseases is expected to propel the growth of the pediatric vaccine market in the coming years. Pediatric diseases are disorders that afflict children between the ages of infancy and puberty. These disorders can be moderate to severe, and they can be either chronic or acute. Pediatric vaccinations are critical to the prevention and control of a wide spectrum of pediatric disorders. They are given to newborns and children to protect them from numerous infectious illnesses. For instance, in February 2024, according to the GOV.UK, a UK-based government department, Cases of tuberculosis (TB) in England increased by 10.7% in 2023, rising from 4,380 in 2022 to 4,850. Therefore, the increasing prevalence of pediatric diseases is driving the pediatric vaccine industry.

Key Players In The Global Pediatric Vaccine Market

Major companies operating in the pediatric vaccine market are Merck & Co. Inc., Serum Institute of India Pvt. Ltd., Sanofi SA, Pfizer Inc., GlaxoSmithKline PLC, Sinovac Biotech Ltd, Zydus Cadila, Indian Immunologicals Limited, Panacea Biotec, Takeda Pharmaceutical Company, Daiichi Sankyo, CSL Limited, Sinopharm, Walvax Biotechnology, Fosun Pharma, MCM Vaccine Company, Seqirus, Johnson & Johnson, Connaught Laboratories Inc., Wyeth-Ayerst, Ataulfo de Paiva Foundation, Bio-Manguinhos – Institute of Technology on Immunobiologicals, Butantan Institute, Ezequiel Dias Foundation (FUNED), Sinergium

Global Pediatric Vaccine Market Trends and Insights

Major companies operating in the pediatric vaccine market are focusing on product approvals to better meet the needs of their existing consumers. ABRYSVO is a vaccine authorized by the FDA for use in pregnant women for the prevention of lower respiratory tract disease (LRTD) and severe LRTD triggered by respiratory syncytial virus (RSV) in children till 6 months of age. For instance, in August 2023, Pfizer Inc., a US-based pharmaceutical manufacturing company announced the U.S. FDA approval of Pfizer's ABRYSVO vaccine for the Avoidance of Respiratory Syncytial Virus (RSV) in Infants by active immunization of pregnant women 32-36 weeks gestational age. The first and only maternal vaccination approved in the United States to help prevent newborns against lower respiratory tract illness (LRTD) and severe LRTD caused by RSV from birth to six months of age.

Regional Insights

North America was the largest region in the pediatric vaccine market in 2025. Middle East is expected to be the largest growing region in the global pediatric vaccine market share during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Pediatric Vaccine Market?

The pediatric vaccine market consists of sales of BCG vaccines, hepatitis B vaccines, pentavalent vaccines, and rotavirus vaccines. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pediatric Vaccine Market Report 2026?

The pediatric vaccine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pediatric vaccine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.